Margaret Chang, MD
Retina Specialist · Sacramento, CANPI 1477504405
Payments from drug & device makers
Across 1,297 payments — averaging $10,191 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7.1M
- Genentech, Inc.$3.2M
- Ocular Therapeutix, Inc.$1M
- Modernatx, Inc.$458K
- Boehringer Ingelheim$358K
- Boehringer Ingelheim International GmbH$311K
- plus $705K from 26 others
Across 35 payments — averaging $1467.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$50K
- Genentech, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $7,099,498 |
| Genentech, Inc. | 245 | $3,244,808 |
| Ocular Therapeutix, Inc. | 91 | $1,041,647 |
| Modernatx, Inc. | 13 | $457,676 |
| Boehringer Ingelheim | 28 | $358,201 |
| Boehringer Ingelheim International GmbH | 253 | $310,882 |
| AstraZeneca | 4 | $289,151 |
| F. Hoffmann-la Roche AG | 408 | $213,470 |
| Regeneron | 53 | $101,593 |
| Genentech USA, Inc. | 66 | $43,394 |
| AbbVie | 8 | $21,951 |
| Roche Products Limited | 5 | $17,709 |
| Mylan Technologies Inc. | 4 | $5,373 |
| Astellas Pharma Global Development | 2 | $2,412 |
| Apellis Pharmaceuticals, Inc. | 29 | $2,067 |
| Eyepoint US, Inc. | 5 | $2,055 |
| Carl Zeiss Meditec, Inc. | 2 | $2,025 |
| Astellas Pharma US Inc | 23 | $2,014 |
| Regeneron Healthcare Solutions, Inc. | 9 | $492 |
| Amgen | 4 | $215 |
| Biogen | 6 | $186 |
| Coherus Oncology, Inc. | 3 | $165 |
| Harrow Eye, LLC | 3 | $161 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $121 |
| Aerie Pharmaceuticals, Inc. | 1 | $115 |
| Mallinckrodt Hospital Products Inc. | 3 | $82 |
| Topcon Healthcare, Inc. | 1 | $60 |
| Alimera Sciences, Inc. | 3 | $57 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Mylan Inc. | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
How this compares
$13,217,715 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Sacramento
- Joel PearlmanSacramento$8.3M
- David TelanderSacramento$780K
- Glenn YiuSacramento$668K
- Carlos Medina MendezSacramento$548K
- Dante PieramiciSanta Barbara$15.1M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.